Modeling Evasive Response Bias in Randomized Response: Cheater Detection Versus Self-protective No-Saying. [PDF]
Sayed KHA +2 more
europepmc +1 more source
Understanding the drivers of sensitive behavior using Poisson regression from quantitative randomized response technique data. [PDF]
Cao M +4 more
europepmc +1 more source
A Systematic Review and Meta‐Analysis of the Recurrence of Autoimmune Encephalitis
ABSTRACT Objective Autoimmune encephalitis (AE) is a disease with a potential for recurrence, and patients receive immunotherapy to prevent it. However, there is no consensus on the duration of immunotherapy. This study aimed to determine the recurrence rate and identify the risk factors for AE to provide guidance on the duration of immunotherapy ...
Shangkai Bai +5 more
wiley +1 more source
A new improved randomized response model with application to compulsory motor insurance. [PDF]
Aboalkhair AM, Elshehawey AM, Zayed MA.
europepmc +1 more source
Asking Sensitive Questions Using the Randomized Response Approach in Public Health Research: An Empirical Study on the Factors of Illegal Waste Disposal. [PDF]
Chong ACY, Chu AMY, So MKP, Chung RSW.
europepmc +1 more source
Multidimensional Profiling of MRI‐Negative Temporal Lobe Epilepsy Uncovers Distinct Phenotypes
ABSTRACT Objective Although hippocampal sclerosis (TLE‐HS) represents the most frequent cause of temporal lobe epilepsy (TLE), up to 30% of patients show no lesion on visual MRI inspection (TLE‐MRIneg). These cases pose diagnostic and therapeutic challenges and are underrepresented in surgical series.
Alice Ballerini +28 more
wiley +1 more source
Randomized Response and Differential Privacy
Andreas Ioannidis +2 more
openaire +1 more source
A class of infinite number of unbiased estimators using weighted squared distance for two-deck randomized response model. [PDF]
Naatjes D, Sedory SA, Singh S.
europepmc +1 more source
RRTCS: An R Package for Randomized Response Techniques in Complex Surveys. [PDF]
Del Mar Rueda M, Cobo B, Arcos A.
europepmc +1 more source
ABSTRACT Objective Onasemnogene abeparvovec (OA) is an AAV9‐based gene therapy for spinal muscular atrophy type I (SMA I). Real‐world outcomes show increased response variability compared to clinical trials, and follow‐up data beyond 12–18 months are limited.
Marika Pane +43 more
wiley +1 more source

